Since
2021
Malta
Devices for treatment
TRL 4

Challenge

Around 1.6 million patients receive total hip arthroplasties (THA) each year. Standard ball-and-socket prostheses only last for approximately 10-25 years, meaning some patients have to undergo the procedure multiple times in their lives. There is also a 1-28% chance of dislocation, depending on risk factors such as revision surgery or misplaced components, that further complicate a patient’s recovery and quality of life.

Opportunity

Though current hip implants already enhance the quality of life of many patients, the high dislocation risk, possibility of reduced mobility, and limited implant lifespan mean there is a significant opportunity for improvement. The increasing demand for replacement or revision surgery (estimated at 8-10% and growing) indicates a pressing need for better and longer-lasting implants.

 

Solution

The Garland implant improves upon standard prostheses by incorporating four independent parts that hinge in three directions, improving the range of motion of the hip and drastically reducing wear. The implant also reduces dislocation risk, while making the surgical assembly procedure easier. The implant is comprised of materials already in clinical use and doesn’t represent a change to the normal surgical procedure for implantation.

Status

The Garland implant has been tested in an accredited implant testing lab in Germany and has undergone initial cadaver studies. A patent application is pending, protecting the unique patent design essential to its superior functionality

Meet the team

DSC_3890_pp

Simon Mifsud

CEO

Gina Melchner (2)

Gina Melchner

Venture Partner

Gina holds a Masters in biotechnology with a focus on synthetic biology from ETH Zurich and worked in management consulting as well as venture capital before joining NLC. She joined NLC as a Venture Developer in February 2020 to help startups succeed and ensure the wealth of innovation surrounding us gets its chance to make a real impact.